Babraham Research Campus
About STORM Therapeutics
STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases.uten-free and surrounding space to commercialize those products in North America.
CEO: Dr Keith Blundy
Please click here for STORM Therapeutics' job opportunities.
11 articles with STORM Therapeutics
A new class of compounds currently in development against acute myeloid leukemia has been discovered to block coronavirus reproduction in human lung cells.
University of Cambridge researchers published the first preclinical validation for a novel therapeutic strategy targeting epitranscriptomic modifiers of RNA, opening the door for spinout STORM Therapeutics’ AML therapy–and potentially much more.
Evotec and Storm Therapeutics Leverage Indigo Platform to Progress Oncology Project Towards Clinical Studies
Evotec SE announced that, as part of its ongoing collaboration with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, STORM has selected STC-15 as a first-in-class development candidate.
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.
Dr Mark Albertella appointed VP Translational Oncology
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor
This appointment follows STORM Therapeutics' successful Series A Financing Extension announced in January 2018.
Taiho Ventures joins the existing blue chip investor syndicate of Merck Ventures, Cambridge Innovation Capital, Pfizer Venture Investments and Touchstone Innovations with an equal size of investment.
These appointments will strengthen STORM's advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.
Storm Therapeutics Announces Publication in Nature on RNA Epigenetics by Founder Professor Tony Kouzarides
The study has found an unexpected new drug target for acute myeloid leukaemia that could open new avenues to develop effective treatments against this potentially lethal disease.
STORM Therapeutics Strengthens Board With Appointment of Professor Paul Workman, President and CEO of the Institute of Cancer Research
This appointment continues STORM's evolution of its management and advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.